Ectopic expression of PTTG1/securin promotes tumorigenesis in human embryonic kidney cells by unknown
BioMed CentralMolecular Cancer
ssOpen AcceResearch
Ectopic expression of PTTG1/securin promotes tumorigenesis in 
human embryonic kidney cells
Tariq Hamid†1,2, Mohammed T Malik†3 and Sham S Kakar*1,2
Address: 1Department of Medicine, University of Louisville, Louisville, KY 40202, USA, 2James Graham Brown Cancer Center, University of 
Louisville, KY 40202, USA and 3Department of Biochemistry and Molecular Biology, University of Louisville, Louisville, KY 40202, USA
Email: Tariq Hamid - t0hami01@louisville.edu; Mohammed T Malik - tariq.malik@louisville.edu; Sham S Kakar* - sskaka01@louisville.edu
* Corresponding author    †Equal contributors
Abstract
Background: Pituitary tumor transforming gene1 (PTTG1) is a novel oncogene that is expressed
in most tumors. It encodes a protein that is primarily involved in the regulation of sister chromatid
separation during cell division. The oncogenic potential of PTTG1 has been well characterized in
the mouse, particularly mouse fibroblast (NIH3T3) cells, in which it induces cell proliferation,
promotes tumor formation and angiogenesis. Human tumorigenesis is a complex and a multistep
process often requiring concordant expression of a number of genes. Also due to differences
between rodent and human cell biology it is difficult to extrapolate results from mouse models to
humans. To determine if PTTG1 functions similarly as an oncogene in humans, we have
characterized its effects on human embryonic kidney (HEK293) cells.
Results: We report that introduction of human PTTG1 into HEK293 cells through transfection
with PTTG1 cDNA resulted in increased cell proliferation, anchorage-independent growth in soft
agar, and formation of tumors after subcutaneous injection of nu/nu mice. Pathologic analysis
revealed that these tumors were poorly differentiated. Both analysis of HEK293 cells transiently
transfected with PTTG1 cDNA and analysis of tumors developed on injection of HEK293 cells that
had been stably transfected with PTTG1 cDNA indicated significantly higher levels of secretion and
expression of bFGF, VEGF and IL-8 compared to HEK293 cells transfected with pcDNA3.1 vector
or uninvolved tissues collected from the mice. Mutation of the proline-rich motifs at the C-terminal
of PTTG1 abolished its oncogenic properties. Mice injected with this mutated PTTG1 either did
not form tumors or formed very small tumors. Taken together our results suggest that PTTG1 is
a human oncogene that possesses the ability to promote tumorigenesis in human cells at least in
part through the regulation of expression or secretion of bFGF, VEGF and IL-8.
Conclusions: Our results demonstrate that PTTG1 is a potent human oncogene and has the
ability to induce cellular transformation of human cells. Overexpression of PTTG1 in HEK293 cells
leads to an increase in the secretion and expression of bFGF, VEGF and IL-8. Mutation of C-
terminal proline-rich motifs abrogates the oncogenic function of PTTG1. To our knowledge, this
is the first study demonstrating the importance of PTTG1 in human tumorigenesis.
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Pituitary tumor transforming gene 1 (PTTG1), a recently
characterized oncogene, was initially identified on analy-
sis of a rat pituitary tumor [1]; subsequently, a human
homologue of PTTG1 was cloned by us and others [2-4].
Three members (PTTG1, PTTG2 and PTTG3) of the PTTG
family, which exhibit differential expression in normal
and tumor cells have been reported [5], although only
PTTG1 has been studied in detail. PTTG1 is located on
chromosome 5q35.1 [6], a locus associated with recurrent
lung cancer and myelogenous leukemias [7]. Moreover, it
has been shown to be expressed highly in various tumors,
and cell lines derived from such tumors, including tumors
of the pituitary, thyroid, colon, ovary, testicles, and breast
[8-12]. In normal tissues, its expression is low or undetec-
table except in testis [4,1]. Recent studies have indicated
that elevated expression of PTTG1 in some tumors may
serve as a prognostic marker for tumor invasiveness and
metastasis [13]. A clue to its function was gained from its
structural similarity with the yeast securin, which led to its
identification as a human securin [14] and suggested that
it may play a role in regulation of sister chromatid separa-
tion. It appears, however, to have multiple effects in cells
with enhanced expression being associated with an
increase in the expression of the c-myc oncogene [15], an
increase in the expression of p53 [16,17], an increase in
the secretion and expression of basic growth factor (bFGF)
[18] and an increase in the secretion and expression of
vascular endothelial growth factor [VEGF) [18,19].
To date, the evidence for the oncogenic function of PTTG1
has been obtained by overexpression of PTTG1 in mouse
fibroblast cells (NIH3T3) followed by assessment of its
ability to induce cellular transformation in vitro (colony
formation in soft agar) and tumor formation in nude mice
[2,4]. Due to the biological differences between human
and rodent cells, however, care must be taken in extrapo-
lating results obtained using rodent cells to human cells.
There are now a number of examples in which it has been
demonstrated that although overexpression of an onco-
gene can induce transformation of primary rodent cells
[20], it fails to induce transformation of the same cell type
derived from humans. Usually this failure is attributable
to the requirement for co-expression of another gene or
oncogenic cooperation of another gene [21-26].
Similarly, much of the evidence concerning the mecha-
nisms by which PTTG1 may affect the phenotype of the
cell has been obtained using transfected NIH3T3 cells. It
is known that the secretion of growth factors and
cytokines by tumor cells, and the cells that infiltrate and
surround the tumor mass play an essential role in the reg-
ulation of tumor growth and metastasis [27]. Both bFGF
and VEGF have been implicated in tumorigenesis and the
expression and secretion of these molecules has been
demonstrated on transfection of NIH3T3 cells with
PTTG1 cDNA [18,19], but this has not been confirmed on
transfection of human cells. The effects of expression of
PTTG1 on another cytokine that is known to play a key
role in tumorigenesis, interleukin-8, (IL-8), have not yet
been analyzed.
The purposes of this study were, therefore, three-fold.
Firstly, to determine whether PTTG1 can induce cellular
transformation of normal human cells; secondly, to deter-
mine if PTTG1 is sufficient in itself to induce transforma-
tion; and, thirdly, to characterize the changes in secretion
and expression of key metastatic, angiogenic and chemok-
ine factors (bFGF, VEGF and IL-8) associated with PTTG1-
mediated transformation in human cells. For these stud-
ies, we selected the human embryonic kidney (HEK293)
cell line as our model. The transformation of these cells by
human adenovirus type 5 prevents their senescence [28].
These cells have been reported to have a moderate tumor-
igenic potential [29] and have been used as a cellular
model for normal human cells to study the oncogenic
potential of a number of genes [29-31]. Mice xenografted
with these cells do not develop tumors even after three
months of injection [31].
Results
Generation of HEK293 cells stably expressing PTTG1 and 
mPTTG1
HEK293 cells were transfected with pcDNA3.1-PTTG1,
pcDNA3.1-mPTTG1 or pcDNA3.1 vector. After G418
selection, 10 clones from each of pcDNA3.1, pcDNA3.1-
PTTG1 or pcDNA3.1-mPTTG1 transfected cells were
picked, cultured and expanded. The PTTG1 protein
expression of these transfectants was detected by western
blot analysis using PTTG1 antiserum. Two representative
clones from PTTG1 transfected (named HEKPTTG1-1 and
HEKPTTG1-3) and mPTTG1 transfected (named
HEKmPTTG1-2 and HEKmPTTG1-4), and one clone from
pcDNA3.1 vector (named HEKpcDNA3.1) was selected
for further studies. Selection of clones was based on the
level of expression of PTTG1 protein. Fig. 1 shows the pro-
tein expression of these clones. Transfection of cells with
the pcDNA3.1 vector resulted in expression of very low
level of PTTG1 protein. The clones of the pcDNA3.1-
PTTG1 and pcDNA3.1-mPTTG1 transfected cells that
exhibited approximately equivalent levels of expression of
PTTG1 and mPTTG1 proteins were processed to establish
stable cell lines.
Stable transfection of PTTG1 induces cell proliferation 
and transformation of HEK293 cells overexpressing 
PTTG1
Previously, we have shown that over expression of PTTG1
in mouse fibroblast NIH3T3 cells results in an increase in
cell proliferation [4]. To determine if over expression ofPage 2 of 13
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Molecular Cancer 2005, 4:3 http://www.molecular-cancer.com/content/4/1/3Western blot analysis of HEK293 cells transfected with pcDNA3.1, pcDNA3.1-PTTG1 or pcDNA3.1-mPTTG1Figure 1
Western blot analysis of HEK293 cells transfected with pcDNA3.1, pcDNA3.1-PTTG1 or pcDNA3.1-mPTTG1. a: 
HEKpcDNA3.1, b: HEKPTTG1-1, c: HEKPTTG1-3, d: HEKmPTTG1-2, and, e: HEKmPTTG1-4 cells.
Cell proliferation of HEK293 cells stably transfected with pcDNA3.1, PTTG1 or m-PTTG1Figure 2
Cell proliferation of HEK293 cells stably transfected with pcDNA3.1, PTTG1 or m-PTTG1. The 5 × 103 cells were plated/well. 
The results are expressed as % of control (HEK293 cells stably transfected with pcDNA3.1 control vector). Error bars repre-
sent ± SEM (n = 4) of three independent experiments.Page 3 of 13
(page number not for citation purposes)
Molecular Cancer 2005, 4:3 http://www.molecular-cancer.com/content/4/1/3PTTG1 in HEK293 cells produces similar effects, we esti-
mated the proliferation at 24, 48, 72 and 96 hours after
plating of stably transfected HEK293 cells expressing high
levels of PTTG1 or mPTTG1 protein. Both clones of
PTTG1-transfected cells (HEKPTTG1-1 and HEKPTTG1-3)
exhibited significantly greater proliferation than the cells
transfected with vector only at all time points tested, and
the time course of proliferation was very similar in both
clones, increasing by 20–30% after 24 hours, 30–40%
after 48 hours. This level of increase in cell proliferation
was retained at least up to 96 hours (Fig. 2). Somewhat
surprisingly, the proliferation of the cells expressing the
mutated PTTG1 was equivalent to that of the cells express-
ing the wild-type PTTG1 and was significantly higher than
that of the cells transfected with vector only (Fig. 2). These
experiments indicate that over expression of PTTG1 does
induce a significant proliferative effect in HEK293 cells;
however, at least under the conditions used, mutation of
the proline-rich motifs of PTTG1 does not affect this
response.
Overexpression of PTTG1 induces cellular transformation
As anchorage-independent growth is considered to be an
in-vitro test for angiogenesis we assayed the effects of
transfection with PTTG1 on the ability of the HEK293
cells to form colonies in soft agar. As shown in Fig. 3, over
expression of PTTG1 in HEK293 cells resulted in a higher
incidence of colony formation than that observed on
transfection with the vector only. The cells transfected
with vector only formed few colonies and these were of
small size during 14 days of culture, whereas both the cell
lines expressing wild type PTTG1 formed a significantly
higher number of colonies, which were of a large size. The
incidence of colony formation was 2% for HEKpcDNA3.1
cell line but was 19% for the HEKPTTG1-1 cell line and
30% for the HEKPTTG1-3 cell line. In this case, mutation
of the proline-rich motifs of PTTG1 resulted in a signifi-
cant reduction in the number of colonies formed with the
incidence of colony formation for the HEKmPTTG1-2 and
HEKmPTTG1-4 cell lines being similar to the vector-only
transfected cells (HEKpcDNA3.1). These results suggest
that over expression of PTTG1 in HEK293 cells induces
cellular transformation, and mutation of proline-rich
motifs does not effect the cell proliferation but abrogates
the cellular transformation ability of PTTG1.
PTTG1 induces tumor formation in nude mice injected 
with HEK293 cells stably expressing PTTG1 protein
To determine whether PTTG1 promotes tumor formation
in nude mice, we subcutaneously injected nude mice with
HEK293 cells expressing PTTG1 or mPTTG1. Three out of
four mice injected with the HEKPTTG1-1 or HEKPTTG1-3
cell lines developed large size tumors within four weeks of
injection (Fig. 4). Pathologic analysis of the tumors
revealed that they were poorly differentiated (Fig. 5). Mice
injected with the HEKmPTTG1-2 cell line did develop
tumors, but the tumors were of a small size. None of the
mice injected with the other cell line-expressing mutant
PTTG1 (HEKmPTTG1-4) or the vector-only cell line
(HEKpcDNA3.1) developed tumors within the time frame
of this experiment (Fig. 4). The tumor volumes, measured
at the end of experiment (six weeks after injection of
cells), were 150–1320 mm3 for HEKPTTG1-1, 72–1404
mm3 for HEKPTTG1-3 and 8.8–12.6 mm3 for
HEKmPTTG1-2 (Table 1). These results clearly demon-
strate that PTTG1 gene is a potent oncogene. Moreover,
they demonstrate that PTTG1 possesses the ability to
enhance the tumorigenic potential of immortal human
cells and that it does not require the ectopic co-expression
of other oncogene(s) to achieve its tumorigenic function.
PTTG1 stimulates expression and secretion of bFGF, VEGF 
and IL-8
Local invasive growth is a key feature of primary malig-
nant tumors. A correlation between the levels of expres-
sion of PTTG1 with increased tumor invasiveness and
with the degree of malignancy has been demonstrated in
pituitary and colorectal tumors [9,35]. The specific mech-
anisms by which PTTG1 facilitates the invasive behaviors
of tumor cells remain obscure, however. Recently,
Ishikawa et al [18] and McCabe et al [19] have shown that
transfection of NIH3T3 cells with PTTG1 cDNA results in
an increase in secretion and expression of both bFGF and
VEGF. A direct correlation between high IL-8 expression
and tumor metastases has been shown in a number of
cancers [36-38], and IL-8 also has been reported to pos-
sess mitogenic [39] and angiogenic effects [40]. We there-
fore measured the levels of bFGF, VEGF and IL-8 in
HEK293 cells transiently transfected with pcDNA3.1 or
pcDNA3.1-PTTG1 cDNA and in tumors developed on
injection of nude mice with HEK293 cells that constitu-
tively express PTTG1. As shown in Fig. 6A, the levels of
bFGF, VEGF and IL-8 were comparatively higher in condi-
tioned medium of cells transfected with pcDNA3.1-
PTTG1 cDNA than from cells transfected with pcDNA3.1
vector only. Cells transfected with pcDNA3.1-PTTG1
showed a 2-fold increase in bFGF, a 3.5-fold increase in
VEGF and a 2-fold increase in IL-8 levels compared to cells
transfected with pcDNA3.1 vector only. Measurement of
the mRNA levels of these factors by RT/PCR showed sig-
nificantly higher levels in cells transfected with
pcDNA3.1-PTTG1 cDNA compared to cells transfected
with pcDNA3.1 vector (Fig. 6B). To determine, if over
expression of PTTG1 results in increase in levels of bFGF,
VEGF and IL-8 in vivo, we measured the levels of bFGF,
VEGF and IL-8 proteins in lysates from tumors developed
on injection of nude mice with HEK293 cells stably trans-
fected with PTTG1. As shown in Fig. 7, the levels of bFGF,
VEGF and IL-8 were significantly higher in three out of
four tumors compared to normal tissues (kidney, liver,Page 4 of 13
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the size of the tumors that developed on injection of cells
expressing mutated PTTG1 (HEKmPTTG1-2) were small,
we were unable to analyze the bFGF, VEGF and IL-8 levels
in these tumors. Measurement of mRNA for bFGF, VEGF
and IL-8 revealed significantly higher levels of expression
in tumors compared to normal tissues and tumors devel-
oped on injection of HEKmPTTG1-2 cells. As expected,
levels of PTTG and mPTTG were higher in tumors as com-
pared to normal tissues (Fig. 8). bFGF levels were found
to be comparatively higher in heart which is consistent
with other investigators [41] Taken together our results
suggest that over expression of PTTG1 in HEK293 cells
results in an increase in secretion and expression of bFGF,
VEGF and IL-8 in vitro and in vivo, suggesting that
increase in secretion and expression of bFGF, VEGF and
IL-8 by PTTG1 may be one of the mechanisms by which
PTTG1 achieves its oncogenic function and increases
tumor angiogenesis.
Discussion
Oncogenic function of PTTG1 was established by its over-
expression in mouse fibroblast cell line (NIH 3T3) fol-
lowed by assessment of its ability to induce cellular
transformation and tumor formation in nude mice [2,4].
However, the differences in biology between the rodent
cells and human cells have brought the validity of this
model into question. There are a number of instances in
which an oncogene has been shown to induce transfor-
mation in rodent cells but has failed to induce transforma-
tion of same types of cells obtained from humans. To test
the ability of PTTG1 to induce transformation in human
cells, we selected the human embryonic kidney-293
(HEK293) cell line as our model. Our data clearly demon-
strate that over expression of PTTG1 in HEK293 results in
an increase in cell proliferation induces cellular transfor-
mation in-vitro (increase in anchorage-independent
growth) and promotes tumor formation in nude mice.
Cells transfected with pcDNA3.1 vector did not form
Colony formation of HEK293 cells stably transfected with pcDNA3.1, pcDNA3.1-PTTG1 or pcDNA3.1-m-PTTG1Figure 3
Colony formation of HEK293 cells stably transfected with pcDNA3.1, pcDNA3.1-PTTG1 or pcDNA3.1-m-PTTG1 a: 
HEKpcDNA3.1, b: HEKPTTG1-1, c: HEKPTTG1-3, d: HEKmPTTG1-2 and e: HEKmPTTG1-4. The data shown is representa-
tive of three independent experiments.Page 5 of 13
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tion in nude mice, confirming that HEK293 cells do not
possess a tumorigenic phenotype. Furthermore our data
suggest that overexpression of PTTG1 in these cells results
in a greater propensity for tumor development, a short-
ened latency period and an enhanced growth rate com-
pared with pcDNA3.1-transfected control HEK293 cells.
A second issue that we were able to address using the
HEK293 cell model was the question of the ability of
PTTG1 to induce transformation of normal human cells,
i.e., whether it acts alone or in cooperation with another
oncogene to achieve its tumorigenic function. It has been
reported that a single oncogene may not be sufficient for
induction of transformation but requires co-expression,
or oncogenic cooperation, of another oncogene(s) to
induce tumorigenesis in normal primary human cells
[20,21,24,25,42,43]. Our results clearly show that PTTG
possess the ability to induce cellular transformation in
vitro and promotes tumor formation in nude mice. Since,
HEK293 cells are transformed with adenovirus type 5 thus
making them different from the normal primary cells,
therefore it remains unclear if PTTG is sufficient by itself
to initiate the tumorigenesis of primary human cells.
However, the data clearly demonstrate that PTTG1 overex-
pression in these cells accelerates their tumorigenic capac-
ity in comparison to that of unmodified cells.
PTTG1 contains several-proline rich motifs (PXXP); two
of these that are located in the C-terminal domain have
been reported to be potential binding sites for SH3-domi-
ans [44]. In our study we confirm that mutation of these
C-terminal proline-rich motifs abrogates the tumorigenic-
ity of PTTG1 in human cells. Such loss of tumorigenicity
on mutation of PTTG1 could be due to a loss of expres-
sion. Our western blot analysis of the stable cell lines
(HEKmPTTG1-2 and HEKmPTTG1-4) that constitutively
express mutated PTTG1 protein showed high levels of
expression of mPTTG1 protein (Fig. 1), suggesting that the
loss of tumorigenic function of mPTTG1 protein is not
due to loss of expression but due to the loss of its ability
to induce cellular transformation. These results are
Tumor development in nu/nu mice on injection of HEK293 cells stably transfected with pcDNA3.1, pcDNA3.1PTTG or pcDNA3.1mPTTG1 cellsFigure 4
Tumor development in nu/nu mice on injection of HEK293 cells stably transfected with pcDNA3.1, pcDNA3.1PTTG or 
pcDNA3.1mPTTG1 cells. Each mouse was injected with 1 × 106 cells. After 6 weeks of injection, mice were photographed and 
sacrificed, tumors and other tissues were collected and tumor volume was measured a: Mouse injected with HEKpcDNA3.1 
cells, b: mouse injected with HEKPTTG1-1 cells, c: mouse injected with HEKPTTG1-3 cells and d: mouse injected with 
HEKmPTTG1-2. Arrows indicate the tumors.Page 6 of 13
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confirm the importance of C-terminal proline-rich motifs
to mediate the oncogenic function of PTTG1.
The molecular mechanisms by which PTTG1 achieves its
tumorigenic function remain unclear. PTTG1 has been
reported to induce expression of the c-myc oncogene [15],
bFGF [18] and VEGF [19]. bFGF is a broad spectrum and
pleiotropic mitogen for growth and differentiation affect-
ing various mammalian cells and organ systems and a
large number of cells lines [45,46]; besides stimulating
wound healing, tissue repair and hematopoiesis [47],
bFGF induces cell migration and proliferation [48] and
acts as an agiogenic factor that induces migration, prolif-
eration and differentiation of endothelial cells [49]. In
addition, it has been reported to modulate the invasion of
tumor cells through surrounding tissue to form new cap-
illary cord structures by regulating the activities of extra-
cellular molecules including collagenase, proteinases and
integrins [49]. Regulation of secretion and expression of
bFGF by PTTG1 in NIH 3T3 cells has been shown [18].
Consistent with these reports, our results demonstrate a
significant increase in secretion and expression of bFGF in
HEK293 cells on transient transfection with PTTG1 cDNA
(Fig. 6) as well as in tumors developed by injection of sta-
ble cell lines that constitutively express PTTG1 both at
protein and mRNAs levels (Figs. 6, 7, 8).
VEGF is a potent stimulant of the vascularization of
tumors and is one of the most specific markers of tumor
vasculature observed to date [50,51]. VEGF is a multifunc-
tional cytokine acting as a potent permeability agent, an
endothelial cell chemotactic agent, an endothelial cell
survival factor and an endothelial cell proliferation factor
Histolopathological analysis of the tumors excised from animals injected with HEK293 cells expressing PTTG1 or m-PTTG1Figure 5
Histolopathological analysis of the tumors excised from animals injected with HEK293 cells expressing PTTG1 or m-PTTG1. 
Tumors were fixed, sectioned and stained for H & E. A: Tumor from animal injected with PTTG1-1, B: Tumor from animal 
injected with HEKPTTG1-3.
Table 1: Tumor formation induced by PTTG1 expressing HEK293 cells in nude mice
Stable Cells Animals with tumor Tumor Volume
HEKpcDNA3.1 0/4 NA
HEKPTTG1-1 3/4 150–1320 mm3
HEKPTTG1-3 3/4 72–1404 mm3
HEKmPTTG1-4 2/4 8.8–12.6 mm3
HEKmPTTG1-2 0/4 NAPage 7 of 13
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shown to be a crucial rate-limiting step during tumor pro-
gression [53]. Our results demonstrate a significant
increase in secretion and expression of VEGF in HEK293
cells on transfection with PTTG1 and also from tumors
excised from animals injected with HEK293 cells that sta-
bly express PTTG1 (Figs. 6, 7, 8).
A direct correlation between high IL-8 expression and
metastases in melanoma [36], ovarian cancer [37], pros-
trate cancer [38] and pancreatic cancer [51] has been
reported. To determine if overexpression of PTTG1
induces change in secretion and expression of IL-8, we
measured its levels in HEK293 cells on transfection with
PTTG1 cDNA and in tumors developed on injection of
HEK293 cells transfected with PTTG1. Our results demon-
strate for the first time that overexpression of PTTG1
induces IL-8 expression in vitro and also in tumors in vivo
(Figs. 6, 7, 8).
Methods
Generation of cell lines constitutively expressing PTTG1
The human embryonic kidney cell line (HEK293), which
had been transfected by exposing these cells to sheared
fragments of adenovirus type 5 DNA [28] was purchased
from ATCC (American Type Culture Collection; Rockville,
Introduction of PTTG in HEK293 cells induces secretion and expression of bFGF, VEGF and IL-8Figure 6
Introduction of PTTG in HEK293 cells induces secretion and expression of bFGF, VEGF and IL-8. HEK293 cells were tran-
siently transfected with pcDNA3.1 or pcDNA3.1-PTTG1 cDNA. The culture medium was collected and lyophilized. bFGF, 
VEGF and IL-8 secreted in culture medium were measured by ELISA. A: Amount of bFGF, VEGF and IL-8 in culture medium. 
Vector: cells transfected with pcDNA3.1 vector DNA; PTTG1: Cells transfected with pcDNA3.1-PTTG1 cDNA. B: Expression 
of bFGF, VEGF and IL-8 mRNA in cells. Lane 1: pcDNA3.1 transfected cells and Lane 2: pcDNA3.1-PTTG1 transfected cells. 
GAPDH was used as an internal control. The data are representative of two independent experiments.Page 8 of 13
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The cells were transfected with pcDNA3.1 vector,
pcDNA3.1-PTTG1 or pcDNA3.1-mPTTG1 to generate sta-
ble clones that constitutively express human wild-type
PTTG1 or mutated PTTG1 (mPTTG1) protein as described
previously [4]. The mPTTG1, which carries a double
amino acid change within the SH3 binding domain of
PTTG1 (P163 to A163, P170 to A170 and P172 to A172, and P173
L173), was generated by site-directed mutagenesis using
the Quick-change mutagenesis kit (Stratagene, La Jolla,
CA) according to the manufacturer's instructions. Muta-
tion of these amino acids has been reported to abrogate
the tumorigenic function of PTTG1 and to block the secre-
tion and expression of bFGF in mouse NIH3T3 cells [2].
Analysis of bFGF, VEGF and IL-8 expression in tumors and other tissuesFigure 7
Analysis of bFGF, VEGF and IL-8 expression in tumors and other tissues. Tumors and other tissues were excised from the ani-
mals injected with HEK293 cells stably transfected with PTTG1 (clone 1 and clone3) and homogenized. bFGF, VEGF and IL-8 in 
the homogenates were analyzed by ELISA. Each analysis was performed in triplicate tissue and was normalized to mg of pro-
tein. Error bars represent ± SEM of three independent experiments.Page 9 of 13
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5'-GATGCTCTCCGCACTCTGGGAATCCAATCTG-3' and
5'-TTCACAAGTTGAGGGGCGCCCAGCTGAAACAG-3'.
The transfected cells were then selected in neomycin G418
(500 µg/ml) and the clones that expressed high levels of
PTTG1 protein or mPTTG1 protein were selected. One
clone from pcDNA3.1 transfected cells (HEKpcDNA3.1)
two clones from pcDNA3.1-PTTG1 transfected cells
Analysis of expression of PTTG bFGF, VEGF and IL-8 mRNAs from tumors and other tissues collected from mice subcutane-ously inject d with HEK293 cells stably expressing PTTG1Figure 8
Analysis of expression of PTTG bFGF, VEGF and IL-8 mRNAs from tumors and other tissues collected from mice subcutane-
ously injected with HEK293 cells stably expressing PTTG1. A: RT-PCR analysis and, B: Western blot analysis. T1: tumor 1, T2: 
tumor 2, M: HEKmPTTG1-2, H: heart, K: Kidney, Li: liver, Lu: lung. GAPDH and β-actin were used as control to examine equal 
loading. The gels are representative of two independent experiments.Page 10 of 13
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pcDNA3.1-mPTTG1 transfected cells (HEKmPTTG1-2
and HEKmPTTG1-4) were propagated into cell lines.
Cell proliferation assay
Cell proliferation was assayed using the CellTiter 96 non-
radioactive cell proliferation assay kit (Promega, Madi-
son, WI) according to the manufacturer's instructions and
as described previously [4]. Briefly, cells growing in log
phase were trypsinized and seeded in 96-well plates
(5,000 cells/well in a final volume of 100 µl) in replicates
of 4 and incubated at 37°C in 5% CO2 and 95% air. After
incubation for 24 h, 48 h, 72 h or 96 h, 20 µl of dye solu-
tion from the kit was added to each well and incubated at
37°C for an additional 2 h. The quantity of formazon
product was measured by its absorbance at 490 nm using
a 96-well plate reader (Molecular Devices, Sunnyvale,
CA). Each experiment was repeated at least three times.
Soft agar colony formation (anchorage-independent cell 
growth) assay
Anchorage-independent cell growth was determined by
analyzing the formation of colonies in soft agar. Cells
(104) from each cell line were suspended in 0.3% agar in
DMEM containing 10% fetal bovine serum and plated on
solidified agar (0.7%) in 35 mm dishes. After 14 days of
culture, colonies formed were counted and photographed
as described previously [4].
In vivo tumor growth assay
Cells growing in log phase were harvested by trypsiniza-
tion and washed twice with PBS. The cells were resus-
pended in PBS to a final concentration of 5 × 106/ml. The
cells (1 × 106 cells in 200 µl PBS/site) were injected subcu-
taneously (s.c.) into both flanks of 5- to 6-week old female
nu/nu mice (4 mice/group) (Charles River Laboratory,
Wilmington, MA). All procedures were carried out follow-
ing the protocol approved by The University of Louisville
Institutional Animal Care and Use Committee. Four
weeks after injection, the mice were scarified, and the
tumors and other tissues harvested. The skin and connec-
tive tissues were dissected from the tumors, and the tumor
volume was calculated from measurements of length ×
width × height. The tissues were divided into two parts,
one part being fixed in 10% buffered formalin and the
other stored in liquid nitrogen. For histopathologic anal-
ysis, 5 µm sections were cut from paraffin-embedded
tissues, and mounted on slides. Sections were stained with
H&E [52], and processed for histopathologic evaluations.
Western blot analysis
Cells growing in log phase were lysed in chilled lysis
buffer [50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1% NP-
40, 1 mM Na3VO4, and 1 mM NaF) supplemented with
Complete Mini Protease Inhibitor tablets (Roche Molecu-
lar Biochemicals, Indianapolis, IN). Equal amounts of
protein extracts (40 µg) were resolved on 12% SDS-PAGE
gel, and transferred onto a nitrocellulose membrane
(Amersham, Piscataway, NJ). Blots were probed with
PTTG1 antiserum at a dilution of 1:1,500 as described pre-
viously [53]. Immunoreactive proteins were visualized
using the Enhanced Chemiluminescent Detection System
(Amersham) according to the instructions provided.
ELISA analysis of bFGF, VEGF and IL-8
The levels of bFGF, VEGF and IL-8 in tissue culture super-
natants and tissue homogenates were measured using
commercially available ELISA kits from BD Biosciences
(Minneapolis, MN). To measure bFGF, VEGF and IL-8 in
the culture supernatants, HEK293 cells were transiently
transfected with pcDNA3.1 or pcDNA3.1-PTTG1 cDNA
using Fugene6 as the transfectant reagent as described pre-
viously [54]. After 24 h of transfection, the medium was
replaced with serum free DMEM medium. Twenty-four
later, the medium was collected and concentrated 5-fold
(1.0 ml to 200 µl) using a speedVac system (Savant, Hol-
brook, NY). To measure bFGF, VEGF and IL-8 in tumor
and other tissues, tissues were homogenized in 50 mM
Tris (pH 7.4), 0.25% Triton X-100, 5 mM EDTA and 0.1%
NP40 supplemented with Complete Mini Protease Inhib-
itor tablets (Roche Molecular Biochemicals, Indianapolis,
IN) using a polytron homogenizer. Homogenates were
centrifuged to remove particulate matter and then diluted
with the diluent provided in the ELISA kit. The concentra-
tion of bFGF, VEGF and IL-8 in a sample was determined
by interpolation from a standard curve. All measurements
were normalized to protein concentration and performed
in triplicate.
Semiquantitative reverse transcriptase/polymerase chain 
reaction (RT/PCR)
Total RNA from tumors and other tissues was purified
using Trizol reagent (Invitrogen, Carlsbad, CA) following
the manufacturer's instructions. The RNA pellets were
resuspended in RNase-free water, and the contaminating
DNA was removed from the preparations with DNaseI.
The yield of total RNA was measured using a
spectrophotometer, and the quality was assessed by elec-
trophoresis through a 1% agarose gel. First strand cDNA
was synthesized using the iScript™ cDNA synthesis kit
(BioRad, Hercules, CA). PCR primers (Table 2) were
designed, based on the human PTTG1, bFGF, VEGF and
IL-8 cDNA sequences. The PCR conditions for each gene
are listed in Table 1. GAPDH amplification was used as an
internal control. Ten µl from a total of 50 µl PCR reaction
mix was applied to a 2% agarose gel and after electro-
phoresis; the gel was stained with ethidium bromide to
visualize PCR products. The densitometric values for the
PCR-amplified products were quantified using BioRad
software and normalized against the GAPDH values.Page 11 of 13
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In summary, our results demonstrate that PTTG1 is a
potent human oncogene and has the ability to induce
cellular transformation of human cells. Overexpression of
PTTG1 in HEK293 cells leads to an increase in the secre-
tion and expression of bFGF, VEGF and IL-8. Mutation of
C-terminal proline-rich motifs abrogates the oncogenic
function of PTTG1. To our knowledge, this is the first
study demonstrating the importance of PTTG1 in human
tumorigenesis.
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